How many drugs treat Acromegaly?

Drug Landscape tracks 7 marketed treatments for Acromegaly (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Acromegaly?

Most recent: Palsonify — EMA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/acromegaly.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Acromegaly — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acromegaly (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acromegaly, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Palsonify	PALTUSOTINE	Crinetics			2025-01-01
Somatuline Depot	LANREOTIDE	Ipsen Pharma	Somatostatin Analog	Somatostatin receptor type 2	2007-01-01
Trovert	somavert	Pfizer	Growth Hormone Receptor Antagonist	Growth hormone receptor	2003-01-01
Trovert	PEGVISOMANT	Pfizer	Growth Hormone Receptor Antagonist	Growth hormone receptor	2003-01-01
Sandostatin	OCTREOTIDE	Novartis	Somatostatin Analog	Somatostatin receptor type 2	1988-01-01
Parlodel	BROMOCRIPTINE	Esjay Pharma	Ergot Derivative	D(2) dopamine receptor	1978-01-01
Bromocriptin	Bromocriptin	University Hospital, Bonn		5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-04-23 — Palsonify · EMA · approved · EU

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Acromegaly
Crinetics · 1 drug in Acromegaly
Esjay Pharma · 1 drug in Acromegaly
· 1 drug in Acromegaly
Novartis · 1 drug in Acromegaly
University Hospital, Bonn · 1 drug in Acromegaly
Ipsen Pharma · 1 drug in Acromegaly

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acromegaly:

Cite this brief

Drug Landscape (2026). Acromegaly — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acromegaly. Accessed 2026-06-10.

Acromegaly full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing